NEW IBS research highlights persistent pain treatment gaps and points to peripheral nerve targets for future, safer therapies.
IBS Pain Remains a Major Clinical Gap
Pain remains one of the most difficult symptoms to treat in irritable bowel syndrome (IBS), according to a new review examining unmet needs in current care and the promise of future therapies aimed at peripheral visceral afferent pathways. While existing IBS management often focuses on bowel dysfunction or central neuromodulators, the review argues that safe and effective pain control is still the field’s greatest unmet need.
The paper outlines how visceral signals travel from the gut to the brain through vagal and pelvic parasympathetic pathways, while noxious stimuli are transmitted through visceral afferents and the spinal cord. This physiology has sharpened interest in the dorsal root ganglion, where first order sensory neuron cell bodies express multiple receptors that may be therapeutically relevant in IBS pain.
IBS Pain Treatment and Peripheral Visceral Afferent Modulation
The review centers on peripheral visceral afferent modulation as a possible new direction for IBS pain treatment. Advances in the understanding of visceral hypersensitivity have led to growing interest in receptors expressed on dorsal root ganglia, particularly as potential drug targets that may reduce pain without relying on centrally acting approaches.
Among the receptor systems discussed are α2 adrenergic, somatostatin SS2, 5-HT3, cannabinoid, nicotinic cholinergic, calcitonin gene related peptide, κ opioid, GLP-1 receptors, and acid gated ion channels. These targets have shown promise in rodent models of visceral hypersensitivity, and some have supporting evidence from randomized controlled trials in IBS.
A Potential Alternative to Central Neuromodulators
The review suggests that novel neuromodulators restricted to peripheral actions could offer a meaningful alternative to central neuromodulators for IBS pain. In addition to pain relief, such therapies may also influence colonic transit or secretion, potentially broadening their clinical relevance.
Although much of the supporting evidence remains preclinical, the overall message is clear: future IBS therapeutics may be most effective when they move closer to the source of pain signaling itself. For clinicians, this review reinforces both the scale of current IBS care gaps and the growing rationale for therapies designed to target peripheral pain pathways more precisely.
Reference
Camilleri M. IBS Clinical Care Gaps and the Potential of Future Therapeutics based on Peripheral Visceral Afferent Modulation. Clin Gastroenterol Hepatol. 2026; DOI: 10.1016/j.cgh.2026.03.038.
Featured Image: amnaj on Adobe Stock.
